- Mithra to receive EUR 20 million upon signing, with further EUR 20 million in potential additional earn-outs
- Agreement covers the sale of the Women’s Health branded generics business in Belgium and Luxembourg as well as License and Supply agreements for certain Mithra assets in the region
- Divestment of BeLux portfolio in line with Mithra’s strategy to realize the value of its noncore assets and fully focus on its key value-driving pipeline
Liège, Belgium, 30 July 2018, 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has signed a comprehensive BeLux partnership with Ceres Pharma, a Belgium-based company focused on over-the-counter (OTC) and specialist healthcare.